NovaBay因1亿美元股票销售协议暴跌

2026-01-21 01:10

NovaBay Pharmaceuticals (NBY) lost ~54% on Tuesday after the wound care product maker announced an at-the-market sales agreement with Virtu Americas, an institutional brokerage firm, to sell up to $100M worth of its common stock.
As part of the agreement signed on Jan. 20, NovaBay (NBY) can offer and sell shares of its common stock at a par value of $0.01 per share, with Virtu serving as its sales agent or principal.
Sales can be made from time to time either through Virtu or to Virtu, the Emeryville, California-based pharma company said in a regulatory filing on Tuesday.
As part of other financial terms of the deal, Virtu is entitled to receive a commission of up to 2.0% of the gross proceeds generated from any sale of common stock it has sold under the sales agreement.

More on NovaBay